Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

The Korean Journal of Internal Medicine
Masahiro Imamura, Junji Tanaka

Abstract

Nonmyeloablative stem cell transplantation (NST) is increasingly used with beneficial effects because it can be applied to older patients with hematological malignancies and those with various complications who are not suitable for conventional myeloablative stem cell transplantation (CST). Various conditioning regimens differ in their myeloablative and immunosuppressive intensity. Regardless of the type of conditioning regimen, graft-versus- host disease (GVHD) in NST occurs almost equally in CST, although a slightly delayed development of acute GVHD is observed in NST. Although graft-versus-hematological malignancy effects (i.e., graft-versus-leukemia effect, graft-versus-lymphoma effect, and graft-versus-myeloma effect) also occur in NST, completely eradicating residual malignant cells through allogeneic immune responses is insufficient in cases with rapidly growing disease or uncontrolled progressive disease. Donor lymphocyte infusion (DLI) is sometimes combined to support engraftment and to augment the graft-versus-hematological malignancy effect, such as the graft-versus-leukemia effect. DLI is especially effective for controlling relapse in the chronic phase of chronic myelogenous leukemia, but not so effective against o...Continue Reading

References

Mar 30, 1989·The New England Journal of Medicine·K M SullivanJ Hansen
Jan 13, 1994·The New England Journal of Medicine·D L PorterJ H Antin
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N T UenoR E Champlin
May 29, 1998·The Journal of Clinical Investigation·P YotndaP Langlade-Demoyen
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L PorterJ H Antin
Feb 29, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·E H WarrenS R Riddell
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MartinelliM Cavo
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·T R SpitzerM Sykes
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck
Jan 10, 2001·Bone Marrow Transplantation·M SalamaR H Collins
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MichalletJ M Boiron
Oct 24, 2002·Current Opinion in Hematology·Jeffrey J MolldremEric Wieder
Dec 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Miho SasakiShigeru Fujita
Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·W A Erik MarijtJ H Frederik Falkenburg

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Software Mentioned

NST

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.